These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31588018)

  • 1. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Hahn AW; Klaassen Z; Agarwal N; Haaland B; Esther J; Ye XY; Wang X; Pal SK; Wallis CJD
    Eur Urol Oncol; 2019 Nov; 2(6):708-715. PubMed ID: 31588018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
    Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
    Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Lombardi P; Filetti M; Falcone R; Di Bidino R; Iacovelli R; Ciccarese C; Bria E; Tortora G; Scambia G; Daniele G
    Cancer Treat Rev; 2022 May; 106():102377. PubMed ID: 35313232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
    Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
    Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.
    Riaz IB; He H; Ryu AJ; Siddiqi R; Naqvi SAA; Yao Y; Husnain M; Narasimhulu DM; Mathew J; Sipra QUAR; Vandvik PO; Joseph RW; Liu H; Wang Z; Herasevich V; Singh P; Hussain SA; Ho TH; Bryce AH; Pagliaro LC; Murad MH; Costello BA
    Eur Urol; 2021 Dec; 80(6):712-723. PubMed ID: 33824031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
    Liu Z; Chen Y; Wei Z; He Y; Wang J; Mu X; He L; Li R; Hu X; Peng X
    Ann Palliat Med; 2021 Mar; 10(3):2805-2814. PubMed ID: 33615806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
    Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
    EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
    Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
    Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
    Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
    ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
    Elaidi R; Phan L; Borchiellini D; Barthelemy P; Ravaud A; Oudard S; Vano Y
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32599839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
    Yanagisawa T; Mori K; Matsukawa A; Kawada T; Katayama S; Bekku K; Laukhtina E; Rajwa P; Quhal F; Pradere B; Fukuokaya W; Iwatani K; Murakami M; Bensalah K; Grünwald V; Schmidinger M; Shariat SF; Kimura T
    Cancer Immunol Immunother; 2024 Jan; 73(2):38. PubMed ID: 38289361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.